Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6101340 | Journal of Hepatology | 2015 | 9 Pages |
Abstract
SummaryEvidence over the past decades have shown that HIV/HCV coinfected patients did not respond as well to HCV therapy as HCV mono-infected patients. However, these paradigms are being recently reassessed with the improvements of care for HIV and HCV patients. This article reviews these original paradigms and how the new data is impacting upon them. Treatment efficacy now appears comparable for HIV/HCV coinfected and HCV mono-infected patients, while liver fibrosis progression is increasingly similar in optimally managed patients. Additional importance of therapy is directed to drug-drug interactions and the impact of HCV reinfection, as well as the possibility of transmitted drug resistance.
Keywords
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Joop E. Arends, Faydra I. Lieveld, Lauke L. Boeijen, Clara T.M.M. de Kanter, Karel J. van Erpecum, Dominique Salmon, Andy I.M. Hoepelman, Tarik Asselah, Andrew Ustianowski,